(Q46594060)

English

Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration

scientific article published in July 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Inhibition of alpha-synuclein fibrillization by dopamine analogs via reaction with the amino groups of alpha-synuclein. Implication for dopaminergic neurodegeneration (English)

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

0 references

0 references

1 reference

based on heuristic

inferred from title

neurodegeneration

1 reference

based on heuristic

inferred from title

author name string

Hong-Tao Li

1

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Dong-Hai Lin

2

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Xiao-Ying Luo

3

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Feng Zhang

4

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Li-Na Ji

5

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Hai-Ning Du

6

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Guo-Qiang Song

7

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Jun Hu

8

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Jia-Wei Zhou

9

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Hong-Yu Hu

10

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

language of work or name

0 references

publication date

1 July 2005

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

272

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

14

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

3661-3672

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

Alpha-synuclein in Lewy bodies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Alpha-synuclein and the Lewy body disorders

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Toxic proteins in neurodegenerative disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

The role of alpha-synuclein in Parkinson's disease: insights from animal models

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Role of alpha-synuclein carboxy-terminus on fibril formation in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Protein oxidation in aging, disease, and oxidative stress

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Effectiveness of anthracycline against experimental prion disease in Syrian hamsters.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Attenuation of dopamine transporter activity by alpha-synuclein

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Mutations in the lipid-binding domain of α-synuclein confer overlapping, yet distinct, functional properties in the regulation of dopamine transporter activity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Vesicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's disease-linked mutations and occurs by a pore-like mechanism.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-4658.2005.04792.X

21 January 2018

Identifiers

10.1111/J.1742-4658.2005.04792.X

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

1 reference

Europe PubMed Central

23 December 2017

http://europepmc.org/abstract/MED/16008565

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46594060&oldid=2165727104"